Adenosine receptors and calcium: basis for proposing a third (A3) adenosine receptor.
D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism / Q000502:physiology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D002118:Calcium / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism; D004095:Dihydropyridines; D005071:Evoked Potentials / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism; D009132:Muscles / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009469:Neuromuscular Junction / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism; D011188:Potassium / Q000378:metabolism / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000145:classification* / Q000187:drug effects / Q000378:metabolism; D011983:Receptors, Purinergic; D012964:Sodium / Q000378:metabolism / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects
D004095:Dihydropyridines; D007473:Ion Channels; D018377:Neurotransmitter Agents; D011725:Pyridines; D011956:Receptors, Cell Surface; D011983:Receptors, Purinergic; C038806:1,4-dihydropyridine; D012964:Sodium; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D000241:Adenosine; D011188:Potassium; D002118:Calcium